APOE and Alzheimer disease: Human studies show that APOE*ε2 is associated with reduced Aβ deposition in the brains of non-demented aged individuals and AD patients [7–11], suggesting that APOE*ε2 reduces AD risk at least partially through Aβ-dependent pathways.